Akero Therapeutics remains a high-risk, clinical-stage biotechnology firm whose valuation is entirely contingent upon the successful development of its MASH therapeutic pipeline.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2025Latest Nov 7, 2025 | -$0.99-5.3% vs -$0.94 | — vs — |
Q3 2025 Aug 8, 2025 | -$0.86+11.3% vs -$0.97 | — vs — |
Q2 2025 May 12, 2025 | $0.90+189.1% vs -$1.01 | — vs — |
Q1 2025 Feb 28, 2025 | -$0.99-1.0% vs -$0.98 | — vs — |
Benchmark AKRO against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Akero Therapeutics, Inc. (AKRO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $54.65 | $4.38B | -14.57 | — | — | -39.22% | — | |
| $399.63 | $9.21B | -31.10 | 432.05% | -10.89% | -27.07% | — | |
| $103.63 | $12.29B | 40.48 | 37.55% | 24.86% | 180.63% | — | |
| $49.43 | $3.53B | -27.01 | — | — | -18.55% | — | |
| $13.28 | $1.54B | -10.89 | 8.28% | -16.78% | -35.81% | — | |
| $20.35 | $1.17B | -8.48 | — | — | -16.91% | — |
Akero Therapeutics, Inc. (AKRO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Akero Therapeutics, Inc. (AKRO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Dec 9, 2025·SEC
Dec 3, 2025·SEC
Oct 9, 2025·SEC
Feb 28, 2025·SEC
Get notified when AKRO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Akero Therapeutics, Inc. (AKRO) stock FAQ — growth, dividends, profitability & financials explained
No. Akero Therapeutics, Inc. (AKRO) reported a net loss of $292.8M over the trailing twelve months.
Akero Therapeutics, Inc. (AKRO) had a return on equity (ROE) of -39.2% in fiscal year 2024. A negative ROE means the company lost money over the period.
Akero Therapeutics, Inc. (AKRO) had negative free cash flow of $250.2M over the trailing twelve months.
